FOLH1 and prostate carcinoma: Positron emission tomography (PET) imaging with the urea-based prostate-specific membrane antigen (PSMA) targeted 68Ga-Glu-NH-CO-Lys-(Ahx)-HBED-CC (68Ga-PSMA-11) has greatly improved the diagnosis and treatment planning for prostate cancer, as upregulated PSMA expression has been linked with aggressive or advanced disease [4, 5].